Candel Therapeutics (CADL) Cash & Equivalents (2020 - 2023)
Historic Cash & Equivalents for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $43.0 million.
- Candel Therapeutics' Cash & Equivalents fell 4428.83% to $43.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $43.0 million, marking a year-over-year decrease of 4428.83%. This contributed to the annual value of $70.1 million for FY2022, which is 1522.71% down from last year.
- According to the latest figures from Q3 2023, Candel Therapeutics' Cash & Equivalents is $43.0 million, which was down 4428.83% from $51.9 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Cash & Equivalents ranged from a high of $94.3 million in Q1 2022 and a low of $24.3 million during Q2 2021
- Its 4-year average for Cash & Equivalents is $64.8 million, with a median of $70.1 million in 2022.
- In the last 5 years, Candel Therapeutics' Cash & Equivalents soared by 25689.26% in 2022 and then crashed by 4428.83% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Cash & Equivalents stood at $35.1 million in 2020, then surged by 135.76% to $82.6 million in 2021, then dropped by 15.23% to $70.1 million in 2022, then crashed by 38.62% to $43.0 million in 2023.
- Its Cash & Equivalents was $43.0 million in Q3 2023, compared to $51.9 million in Q2 2023 and $59.3 million in Q1 2023.